Brookline Capital analyst Leah Cann maintains MEI Pharma (NASDAQ:MEIP) with a Buy and announces $80 price target.
Brookline Capital Maintains Buy on MEI Pharma, Announces $80 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.